3,822
Views
23
CrossRef citations to date
0
Altmetric
Editorial

A deadly spillover: SARS-CoV-2 outbreak

ORCID Icon, ORCID Icon, , &
Pages 481-485 | Received 23 Mar 2020, Accepted 22 Apr 2020, Published online: 29 Apr 2020

Figures & data

Figure 1. Open reading frame 1 (ORF1) genomic organization of SARS-CoV-2. In the orange boxes, the four enzymes that might be targeted by antiviral drugs: papain-like protease (PLP), main protease (MP), RNA-dependent RNA polymerase (RdRp) and helicase.

Figure 1. Open reading frame 1 (ORF1) genomic organization of SARS-CoV-2. In the orange boxes, the four enzymes that might be targeted by antiviral drugs: papain-like protease (PLP), main protease (MP), RNA-dependent RNA polymerase (RdRp) and helicase.

Figure 2. Alignment of the PLPs from the three CoV. Multiple amino acid sequence alignment was performed with the program ClustalW, version 2.1. The alignment was formatted highlighting in black the identical residues and the conservative substitutions in gray.

Figure 2. Alignment of the PLPs from the three CoV. Multiple amino acid sequence alignment was performed with the program ClustalW, version 2.1. The alignment was formatted highlighting in black the identical residues and the conservative substitutions in gray.

Figure 3. Multiple amino acid sequence alignment of the MPs from SARS-CoV, MERS-CoV, and SARS-CoV-2 carried out with ClustalW, version 2.1. The formatted alignment shows the identical amino acid residues (black) and the conservative substitutions (gray).

Figure 3. Multiple amino acid sequence alignment of the MPs from SARS-CoV, MERS-CoV, and SARS-CoV-2 carried out with ClustalW, version 2.1. The formatted alignment shows the identical amino acid residues (black) and the conservative substitutions (gray).

Figure 4. Drugs and drug candidates with some efficacy against SARS-CoV-2.

Figure 4. Drugs and drug candidates with some efficacy against SARS-CoV-2.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.